Clinical Trial

Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 27, 2022 (before its estimated October 19, 2024 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to determine the efficacy and safety of pulsed radiotherapy given concomitantly with Tislelizumab and as maintenance therapy in participants with locoregionally recurrent head and neck squamous cell carcinoma ( HNSCC).
Trial Details
NCT Number NCT05595590
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Head and Neck Cancer
Enrollment 20 participants
Start Date 2022-10-20
Primary Completion 2024-10-19 (estimated)
Study Completion 2026-10-19 (estimated)
Updated on ClinicalTrials.gov 2022-10-27